AstraZeneca Neuroscience Innovative Medicines (AZ NS iMed) has signed an agreement with ePharmaSolutions for IT solutions that will enable the AZ unit to share and manage complex data on a common portal with clinical trial investigators and other external partners, with an electronic trial master file (eTMF) solution and cloud technology for sharing documents securely. Initially, the ePharmaSolutions technology will be used to manage three neuroscience trials. “A key strategy for our business is crafted around relationship building and leveraging innovative solutions for data sharing with collaborators,” said Steven Leventer, Ph.D., vice president, AZ NS iMed. “The capabilities brought to the table by ePharmaSolutions are aimed at enabling the AZ NS iMed to ramp up our clinical trial sites more quickly and efficiently.” “We are very pleased to have been selected by the AZ NS iMed team for this collaboration,” said Lance Converse, founder and chief executive officer of ePharmaSolutions. “Our integrated trial portal, document exchange and eTMF platform will play a pivotal role in supporting the study teams as well as the investigator sites.”